| Method of stimulating the motility of the gastrointestinal system using growth hormone secretagogues -> Monitor Keywords |
|
|
 
Method of stimulating the motility of the gastrointestinal system using growth hormone secretagoguesRelated Patent Categories: Drug, Bio-affecting And Body Treating Compositions, Designated Organic Active Ingredient Containing (doai), Peptide Containing (e.g., Protein, Peptones, Fibrinogen, Etc.) Doai, Cyclopeptides, 2 Peptide Repeating Units In Known Peptide ChainMethod of stimulating the motility of the gastrointestinal system using growth hormone secretagogues description/claimsThe Patent Description & Claims data below is from USPTO Patent Application 20070191283, Method of stimulating the motility of the gastrointestinal system using growth hormone secretagogues. Brief Patent Description - Full Patent Description - Patent Application Claims
[0001] This application claims priority to U.S. Provisional Patent Application-Ser. No. 60/600,959 filed Aug. 12, 2004, the disclosure of which is incorporated herein by reference in its entirety. BACKGROUND OF THE INVENTION [0002] Gastrointestinal (GI) motility is a coordinated neuromuscular process that transports nutrients through the digestive system. C. Scarpignato, "Pharmacological Stimulation of Gastrointestinal Motility: Where We Are And Where Are We Going?" Dig. Dis., 15: 112 (1997). Impaired (i.e., slowed) motility of the gastrointestinal system, which can be involved in gastroesophageal reflux disease, gastroparesis (e.g., diabetic and postsurgical), irritable bowel syndrome and constipation, is one of the largest health care burdens of industrialized nations. S. D. Feighner et al., "Receptor for Motilin Identified in the Human Gastrointestinal System," Science, 284: 2184-2188 (Jun. 25, 1999). [0003] In view of the above, an effective, physiological way to stimulate motility of the gastrointestinal system is highly desirable. SUMMARY OF THE INVENTION [0004] The present invention relates to a method of stimulating the motility of the gastrointestinal system in a subject in need thereof, wherein the subject suffers from maladies (i.e., disorders or diseases) of the gastrointestinal system. The method comprises administering to a subject in need thereof a therapeutically effective amount of a growth hormone secretagogue compound or a pharmaceutically acceptable salt, hydrate or solvate thereof. [0005] In one embodiment, stimulation of gastrointestinal motility is used in a method of treating opioid induced constipation in a subject in need thereof comprising administering a therapeutically effective amount of a growth hormone secretagogue compound or a pharmaceutically acceptable salt, hydrate or solvate thereof. In one embodiment, the subject is using opioids for post-surgical pain management. In another embodiment, the subject is using opioids for chronic pain management. Suitable opioids included, but are not limited to, percocet, morphine, vicoden, methadone, oxycodone and fentanyl. In a particular embodiment, the growth hormone secretagogue is represented by Formulas I-V, or a pharmaceutically acceptable salt, hydrate or solvate thereof. [0006] In another embodiment, stimulation of gastrointestinal motility is used in a method of treating diabetes related gastroparesis in a subject in need thereof comprising administering a therapeutically effective amount of a growth hormone secretagogue compound. In a particular embodiment, the growth hormone secretagogue is represented by Formulas I-V, or a pharmaceutically acceptable salt, hydrate or solvate thereof. [0007] In a further embodiment, stimulation of gastrointestinal motility is used in a method of treating gastroesophageal reflux disease (GERD) in a subject in need thereof comprising administering a therapeutically effective amount of a growth hormone secretagogue compound. In a particular embodiment, the growth hormone secretagogue is represented by Formulas I-V, or a pharmaceutically acceptable salt, hydrate or solvate thereof. In a particular embodiment, the gastroesophageal reflux disease is nocturnal gastroesophageal reflux disease. [0008] In yet another embodiment, stimulation of gastrointestinal motility is used in a method of treating irritable bowel syndrome (IBS) in a subject in need thereof comprising administering a therapeutically effective amount of a growth hormone secretagogue compound. In a particular embodiment, the growth hormone secretagogue is represented by Formulas I-V, or a pharmaceutically acceptable salt, hydrate or solvate thereof. In one embodiment, the irritable bowel syndrome is constipation-predominant irritable bowel syndrome. In another embodiment, the irritable bowel syndrome is alternating constipation/diarrhea irritable bowel syndrome. [0009] In one embodiment, stimulation of gastrointestinal motility is used in a method of treating constipation in a subject in need thereof comprising administering a therapeutically effective amount of a growth hormone secretagogue compound. In a particular embodiment, the growth hormone secretagogue is represented by Formulas I-V, or a pharmaceutically acceptable salt, hydrate or solvate thereof. [0010] In one embodiment, stimulation of gastrointestinal motility is used in a method of treating post-operative ileus in a subject in need thereof comprising administering a therapeutically effective amount of a growth hormone secretagogue compound. In a particular embodiment, the growth hormone secretagogue is represented by Formulas I-V, or a pharmaceutically acceptable salt, hydrate or solvate thereof. [0011] In a particular embodiment, the growth hormone secretagogue is represented by the structural Formula I: wherein: [0012] R.sup.1 is hydrogen, or C.sub.1-6-alkyl optionally substituted with one or more aryl or hetaryl; [0013] a and d are independently 0, 1, 2 or 3; [0014] b and c are independently 0, 1, 2, 3, 4 or 5, provided that b+c is 3, 4 or 5; [0015] D is R.sup.2--NH--(CR.sup.3R.sup.4).sub.e--(CH.sub.2).sub.f-M-(CHR.sup.5).sub.- g--(CH.sub.2).sub.h-- wherein: [0016] R.sup.2, R.sup.3, R.sup.4 and R.sup.5 are independently hydrogen or C.sub.1-6 alkyl optionally substituted with one or more halogen, amino, hydroxyl, aryl or hetaryl; or [0017] R.sup.2 and R.sup.3 or R.sup.2 and R.sup.4 or R.sup.3 and R.sup.4 can optionally form --(CH.sub.2).sub.i--U--(CH.sub.2).sub.j--, wherein i and j are independently 1 or 2 and U is --O--, --S-- or a valence bond; [0018] h and f are independently 0, 1, 2, or 3; [0019] g and e are independently 0 or 1; [0020] M is a valence bond, --CR.sup.6.dbd.CR.sup.7--, arylene, hetarylene, --O-- or --S--; [0021] R.sup.6 and R.sup.7 are independently hydrogen, or C.sub.1-6-alkyl optionally substituted with one or more aryl or hetaryl; Continue reading about Method of stimulating the motility of the gastrointestinal system using growth hormone secretagogues... Full patent description for Method of stimulating the motility of the gastrointestinal system using growth hormone secretagogues Brief Patent Description - Full Patent Description - Patent Application Claims Click on the above for other options relating to this Method of stimulating the motility of the gastrointestinal system using growth hormone secretagogues patent application. ###  How KEYWORD MONITOR works... a FREE service from FreshPatents1. Sign up (takes 30 seconds). 2. Fill in the keywords to be monitored. 3. Each week you receive an email with patent applications related to your keywords. Start now! - Receive info on patent apps like Method of stimulating the motility of the gastrointestinal system using growth hormone secretagogues or other areas of interest. ### Previous Patent Application: Compounds for enzyme inhibition Next Patent Application: D-ribose for improving depression-like symptoms Industry Class: Drug, bio-affecting and body treating compositions ### FreshPatents.com Support Thank you for viewing the Method of stimulating the motility of the gastrointestinal system using growth hormone secretagogues patent info. IP-related news and info Results in 0.4435 seconds Other interesting Feshpatents.com categories: Canon USA , Celera Genomics , Cephalon, Inc. , Cingular Wireless , Clorox , Colgate-Palmolive , Corning , Cymer , 174 |
 * Protect your Inventions * US Patent Office filing 
PATENT INFO |
|
